Home › Funds › Summit Global Investments › NBIX

Summit Global Investments position in NBIX

NEUROCRINE BIOSCIENCES INC · Health Care

Summit Global Investments reported holding 29,424 shares of NBIX (NEUROCRINE BIOSCIENCES INC) in its Q2 2026 13F filing — a position valued at US$5.0M, representing 0.27% of its reported portfolio and ranking #45 among its reported holdings. Summit Global Investments has disclosed NBIX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)29.42K sh
Reported value held$4.96M
Portfolio Weight0.27%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Summit Global Investments's NBIX position evolved

Summit Global Investments first disclosed a stake in NBIX in Q3 2023 at 30,037 shares (US$3.4M). The position peaked in Q2 2024 at 77,601 shares, worth US$10.7M. Across 12 filings, Summit Global Investments increased the stake 6 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 29,424 shares valued at US$5.0M — an increase of 12,341 shares quarter over quarter.. Notable position changes include a 66% trim in Q1 2025 (shares rose 14% over the following quarter), a 214% increase in Q3 2025 (shares rose 1% over the following quarter), a 72% increase in Q2 2026 (shares fell 16% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 30.04K $3.38M New
Q4 2023 40.73K $5.37M Add
Q1 2024 49.48K $6.82M Add
Q2 2024 77.60K $10.68M Add
Q3 2024 53.58K $6.17M Reduce
Q4 2024 32.06K $4.38M Reduce
Q1 2025 10.88K $1.20M Reduce
Q2 2025 11.52K $1.45M Add
Q3 2025 36.16K $5.08M Add
Q4 2025 24.80K $3.52M Reduce
Q1 2026 17.08K $2.25M Reduce
Q2 2026 29.42K $4.96M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NBIX and 13F data

NBIX (NEUROCRINE BIOSCIENCES INC) is a Health Care company. 34 other funds we track also report a position in NBIX — the largest reported positions include Renaissance Technologies (US$393.7M), Two Sigma Investments (US$349.9M), Vestal Point Capital, LP (US$316.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NBIX

All NBIX fund holders →

FAQ

How long has Summit Global Investments held NBIX?

Summit Global Investments has disclosed NBIX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Summit Global Investments's current position in NBIX?

As of Q2 2026, Summit Global Investments holds 29.42K shares of NBIX (NEUROCRINE BIOSCIENCES INC), valued at $4.96M, representing 0.27% of its reported portfolio and ranking #45.

Has Summit Global Investments been buying or selling NBIX?

In the latest 13F filing (Q2 2026), Summit Global Investments increased its position in NBIX. The position peaked in Q2 2024 at 77.60K shares.

Which other funds hold NBIX?

Other major institutional holders of NBIX include Renaissance Technologies, Two Sigma Investments, Vestal Point Capital, LP, among 34 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.